IL80149A - Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases - Google Patents

Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases

Info

Publication number: IL80149A
Authority: IL; Israel
Prior art keywords: diseases; toluidide; versus; pharmaceutical compositions; compositions containing
Prior art date: 1985-09-27

Application number

IL80149A

Other languages

English (en)

Original Assignee

Hoechst Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-09-27

Filing date

1986-09-25

Publication date

1990-11-29

1986-09-25 Application filed by Hoechst Ag filed Critical Hoechst Ag

1990-11-29 Publication of IL80149A publication Critical patent/IL80149A/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/23—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same unsaturated acyclic carbon skeleton
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pyrane Compounds (AREA)

IL80149A 1985-09-27 1986-09-25 Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases IL80149A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19853534440 DE3534440A1 (de)	1985-09-27	1985-09-27	Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes

Publications (1)

Publication Number	Publication Date
IL80149A true IL80149A (en)	1990-11-29

Family

ID=6282084

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL80149A IL80149A (en)	1985-09-27	1986-09-25	Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases

Country Status (11)

Country	Link
US (1)	US4965276A (xx)
EP (2)	EP0559238B1 (xx)
JP (3)	JP2514190B2 (xx)
AT (1)	ATE122033T1 (xx)
AU (1)	AU588629B2 (xx)
CA (1)	CA1275251C (xx)
DE (3)	DE3534440A1 (xx)
ES (1)	ES2001996A6 (xx)
IE (1)	IE61232B1 (xx)
IL (1)	IL80149A (xx)
ZA (1)	ZA867347B (xx)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5268382A (en) *	1985-09-27	1993-12-07	Hoechst Aktiengesellschaft	Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
US4975462A (en) *	1988-07-29	1990-12-04	Bristol-Myers Company	Antiarthritic α-arylcarbamoyl cyanoacetic acid derivatives
DD297328A5 (de) *	1989-08-18	1992-01-09	��@��k��Kk��	5-methyl-isoxalol-4-carbonsaeureanilide und 2 hydroxyethyliden-cyanoessigsaeureanilide zur behandlung von augenerkrankungen
US5583150A (en) *	1989-08-18	1996-12-10	Alcon Laboratories, Inc.	5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
US5268389A (en) *	1989-10-16	1993-12-07	Uniroyal Chemical Company, Inc.	Thiocarboxylate ester compounds compositions containing the same
US5001124A (en) *	1990-02-02	1991-03-19	Syntex (U.S.A.) Inc.	4-isoxazolecarboxamide derivatives
US5108999A (en) *	1990-02-02	1992-04-28	Syntex (U.S.A.) Inc.	4-isoxazolecarboxamide derivatives
HU222234B1 (hu) *	1990-05-18	2003-05-28	Aventis Pharma Deutschland Gmbh.	Eljárás izoxazol-4-karbonsav-amidok és hidroxi-alkilidén-cián-ecetsav-amidok, a vegyületeket tartalmazó gyógyászati készítmények és az ismert vegyületeket tartalmazó rákellenes hatású gyógyszerkészítmények előállítására
DE4127737A1 (de) *	1991-08-22	1993-02-25	Hoechst Ag	Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
US6133301A (en) *	1991-08-22	2000-10-17	Aventis Pharma Deutschland Gmbh	Pharmaceuticals for the treatment of rejection reactions in organ transplantations
ATE128353T1 (de) *	1991-10-23	1995-10-15	Hoechst Ag	N-phenyl-2-cyano-3-hydroxycrotonsäureamidderiva e und deren verwendung als arzneimittel mit immunmodulatorischer eigenschaft.
GB9200275D0 (en) *	1992-01-08	1992-02-26	Roussel Lab Ltd	Chemical compounds
GB9300083D0 (en)	1993-01-05	1993-03-03	Roussel Lab Ltd	Chemical compounds
ATE174217T1 (de) *	1993-01-08	1998-12-15	Hoechst Ag	Verwendung von leflunomid zur hemmung von interleukin 1 alpha
EP0607776B1 (de) *	1993-01-08	1998-12-09	Hoechst Aktiengesellschaft	Verwendung von Leflunomid zur Hemmung von Tumornekrosefaktor alpha
ES2125356T3 (es) *	1993-01-08	1999-03-01	Hoechst Ag	Empleo de leflunomida para la inhibicion de interleuquina 8.
EP0607775B1 (de) *	1993-01-08	1998-12-09	Hoechst Aktiengesellschaft	Verwendung von Leflunomid zur Hemmung von Interleukin 1 beta
TW314467B (xx) *	1993-03-31	1997-09-01	Hoechst Ag
WO1994024095A1 (en) *	1993-04-16	1994-10-27	Abbott Laboratories	Immunosuppressive agents
LT3589B (en)	1993-11-30	1995-12-27	Hoechst Ag	Using of known combination for treatment of rejection reaction by transplantation of organs
US5700823A (en) *	1994-01-07	1997-12-23	Sugen, Inc.	Treatment of platelet derived growth factor related disorders such as cancers
US5519042A (en) *	1994-01-13	1996-05-21	Hoechst Aktiengesellschaft	Method of treating hyperproliferative vascular disease
US5624946A (en) *	1994-07-05	1997-04-29	Williams; James	Use of leflunomide to control and reverse chronic allograft rejection
ES2148561T3 (es) *	1994-10-17	2000-10-16	Aventis Pharma Ltd	Prevencion y curacion de enfermedades alergicas de tipo i.
DE19610955A1 (de)	1996-03-20	1997-09-25	Hoechst Ag	Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
DE19612131A1 (de) *	1996-03-27	1998-01-22	Hoechst Ag	Feste Arzneistoffzubereitung, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl) -anilid
US6011051A (en) *	1996-07-31	2000-01-04	Hoechst Aktiengesellschaft	Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
DE19702988A1 (de)	1997-01-28	1998-07-30	Hoechst Ag	Isoxazol- und Crotonsäureamidderivate und deren Verwendung als Arzneimittel und Diagnostika
US6316479B1 (en)	1997-05-19	2001-11-13	Sugen, Inc.	Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
US7691890B2 (en)	1998-03-11	2010-04-06	James W. Williams	Anti-viral uses of leflunomide products
US20050255071A1 (en) *	1998-12-10	2005-11-17	Aventis Pharma Deutschland Gmbh	Preparation having improved therapeutic breadth comprising nucleotide synthesis inhibitors
DE19908527C2 (de) *	1999-02-26	2001-08-30	Aventis Pharma Gmbh	Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid
DE19960443C2 (de) *	1999-12-15	2002-05-08	Aventis Pharma Gmbh	Verfahren zur Auffindung von Nukleotidsyntheseinhibitoren mit weniger Nebenwirkungen
HRP20050176A2 (en) *	1999-12-16	2005-08-31	Teva Pharmaceutical Industries Ltd.	Novel processes for making - and a new crystalline form of-leflunomide
DE60226855D1 (de)	2001-04-05	2008-07-10	Aventis Pharma Inc	Verwendung von (z)-2-cyano-3-hydroxy-but-2-ensäure-(4'-trifluoromethylphenyl)-amid zur behandlung der multiplen sklerose
GB0123571D0 (en)	2001-04-05	2001-11-21	Aventis Pharm Prod Inc	Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
MXPA04000224A (es)	2001-07-10	2005-07-25	4Sc Ag	Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos.
CA2509139C (en)	2002-12-23	2012-03-20	4Sc Ag	Aromatic compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
EP1768662A2 (en)	2004-06-24	2007-04-04	Novartis Vaccines and Diagnostics, Inc.	Small molecule immunopotentiators and assays for their detection
US20060024376A1 (en) *	2004-07-30	2006-02-02	The University Of Chicago	Methods and compositions for reducing toxicity associated with leflunomide treatment
CN104739821B (zh)	2009-09-18	2018-04-06	赛诺菲	稳定性提高的(z)‑2‑氰基‑3‑羟基‑丁‑2‑烯酸‑(4’‑三氟甲基苯基)‑酰胺片剂制剂
WO2011116091A1 (en)	2010-03-17	2011-09-22	Novartis Ag	Dispenser
UA108760C2 (uk)	2010-07-01	2015-06-10		Кальцієві солі сполуки як протизапальні, імуномодулюючі та антипроліферативні засоби
CN105395539A (zh) *	2014-08-21	2016-03-16	欣凯医药化工中间体（上海）有限公司	泰瑞米特钠在制备治疗自身免疫病药物中的应用
WO2017056104A1 (en)	2015-09-28	2017-04-06	Natco Pharma Limited	Stable pharmaceutical compositions of teriflunomide
JOP20190207A1 (ar)	2017-03-14	2019-09-10	Actelion Pharmaceuticals Ltd	تركيبة صيدلانية تشتمل على بونيسيمود
HRP20240695T1 (hr)	2018-03-16	2024-08-16	Immunic Ag	Novi polimorfi kalcijeve soli kao protuupalna, imunomodulatorna i anti-proliferacijska sredstva
WO2021214033A1 (en)	2020-04-21	2021-10-28	Immunic Ag	Vidofludimus for use in the treatment or prevention of viral diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL186239B (nl) *	1975-06-05		Hoechst Ag	Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
DK545976A (da) *	1975-12-11	1977-06-12	Hoechst Ag	Cyaneddikesyreanilidderivater fremgangsmade til deres fremstilling og midler der indeholder disse forbindelser
DE2555789A1 (de) *	1975-12-11	1977-07-07	Hoechst Ag	Neue cyanessigsaeureanilid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
DE2854439A1 (de) *	1978-12-16	1980-07-03	Hoechst Ag	Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
EP0043150A1 (en) *	1980-06-24	1982-01-06	Akzo N.V.	Pharmaceutical 2,3 -bis-hydroxybenzyl butane derivatives
US4435407A (en) *	1982-01-07	1984-03-06	Ciba-Geigy Corporation	Certain substituted β-oxo-α-carbamoylpyrrolepropionitriles
US4435387A (en) *	1982-10-25	1984-03-06	American Cyanamid Company	Poly-cation salts of bis (or tris) 4-O-polyhexose-thio-arylene sulfate derivatives
DE3405727A1 (de) *	1984-02-17	1985-08-22	Hoechst Ag, 6230 Frankfurt	Isoxazol-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB8619432D0 (en) *	1986-08-08	1986-09-17	Lilly Industries Ltd	Pharmaceutical compounds

1985
- 1985-09-27 DE DE19853534440 patent/DE3534440A1/de not_active Withdrawn
1986
- 1986-09-13 EP EP93106367A patent/EP0559238B1/de not_active Expired - Lifetime
- 1986-09-13 DE DE86112687T patent/DE3689252D1/de not_active Expired - Lifetime
- 1986-09-13 AT AT93106367T patent/ATE122033T1/de not_active IP Right Cessation
- 1986-09-13 DE DE3650315T patent/DE3650315D1/de not_active Expired - Lifetime
- 1986-09-13 EP EP86112687A patent/EP0217206B1/de not_active Expired - Lifetime
- 1986-09-25 IL IL80149A patent/IL80149A/xx not_active IP Right Cessation
- 1986-09-25 US US06/911,328 patent/US4965276A/en not_active Expired - Lifetime
- 1986-09-26 ES ES8602206A patent/ES2001996A6/es not_active Expired
- 1986-09-26 AU AU63167/86A patent/AU588629B2/en not_active Expired
- 1986-09-26 IE IE255486A patent/IE61232B1/en not_active IP Right Cessation
- 1986-09-26 ZA ZA867347A patent/ZA867347B/xx unknown
- 1986-09-26 CA CA000519220A patent/CA1275251C/en not_active Expired - Lifetime
- 1986-09-26 JP JP61226368A patent/JP2514190B2/ja not_active Expired - Lifetime
1992
- 1992-12-02 JP JP4322998A patent/JPH0729918B2/ja not_active Expired - Lifetime
1994
- 1994-09-14 JP JP6219865A patent/JP2607848B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
ES2001996A6 (es)	1988-07-01
JP2607848B2 (ja)	1997-05-07
IE862554L (en)	1987-03-27
EP0217206A2 (de)	1987-04-08
DE3534440A1 (de)	1987-04-02
ATE122033T1 (de)	1995-05-15
JPH05208908A (ja)	1993-08-20
EP0217206A3 (en)	1989-06-14
EP0559238B1 (de)	1995-05-03
JPS6272614A (ja)	1987-04-03
EP0217206B1 (de)	1993-11-03
CA1275251C (en)	1990-10-16
JP2514190B2 (ja)	1996-07-10
JPH0729918B2 (ja)	1995-04-05
DE3689252D1 (de)	1993-12-09
AU6316786A (en)	1987-04-02
DE3650315D1 (de)	1995-06-08
EP0559238A1 (de)	1993-09-08
ZA867347B (en)	1987-05-27
IE61232B1 (en)	1994-10-19
AU588629B2 (en)	1989-09-21
JPH07165694A (ja)	1995-06-27
US4965276A (en)	1990-10-23

Publication	Publication Date	Title
IL80149A (en)	1990-11-29	Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
SE8300736D0 (sv)	1983-02-11	Novel pharmacologically active compounds
EG17753A (en)	1991-12-30	Novel pharmacological compounds
NZ244021A (en)	1995-01-27	Benzylthiazolidinedione derivatives, preparation and pharmaceutical compositions thereof
MY101784A (en)	1992-01-17	Novel pharmacological compounds
IL84944A (en)	1992-02-16	Pharmaceutical compositions containing 1,2-dihydro-3h-indazolone derivatives,some new such compounds and their preparation
ES8307210A1 (es)	1983-07-01	Procedimiento para la obtencion de nuevos derivados de omega-ciano-1, omega-difenil-aza-alcano.
GR3006091T3 (xx)	1993-06-21
ZA905861B (en)	1991-07-31	Pharmaceutical composition for oral administration containing nac
DE3583765D1 (de)	1991-09-19	Hydantoinderivate und diese enthaltende pharmazeutische zusammensetzungen.
PH27446A (en)	1993-07-02	Compound with gastric acid inhibitory effect
IT9019112A1 (it)	1991-07-19	Composizioni farmaceutiche e forme di dosaggio per la somministrazione orale di calcitonina
PH19471A (en)	1986-05-14	Oxindole derivatives and pharmaceutical composition containing them
IL89335A (en)	1993-08-18	6-oxo-pyridazine derivatives, a process for their preparation and pharmaceutical compositions containing these compounds
IL89377A0 (en)	1989-09-10	Substituted imidazolinones and imidazolinethiones,their preparation and pharmaceutical compositions containing them
NZ216246A (en)	1989-08-29	2-azabicyclo(3.3.0 -7-octene-3-carboxylic acid derivatives and pharmaceutical compositions
IL85508A (en)	1991-11-21	2-substituted-4-(2-benzyl-aminophenyl)-1,4,5,7-tetra-hydro-5-oxofuro(3,4,-b)-pyridine-3-carboxylic acid derivatives and pharmaceutical compositions containing them
JO1531B1 (en)	1989-01-25	New near-compounds
ITMI911093A0 (it)	1991-04-19	Composizione farmaceutica contenente un'associazione di 3,4-di-o isobutirril-epinina ed isosorbide-5- monoidrato
IT8819541A0 (it)	1988-02-25	Composizione farmaceutica per somministrazione nasale.
NO964775L (no)	1993-01-27	Fast farmasöytisk adenosinholdig preparat

Legal Events

Date	Code	Title
1996-12-05	KB	Patent renewed
2001-08-26	HP	Change in proprietorship
2004-11-10	KB	Patent renewed
2006-12-07	EXP	Patent expired